Citron's Andrew Left: I'd Love Mallinckrodt to Sue Me

The transcript discusses allegations of securities fraud against Mallinckrodt, focusing on misleading revenue claims related to government reimbursements. It highlights legal and ethical concerns, questioning the efficacy of the drug Akhtar. The discussion also touches on political and economic implications, emphasizing the need for healthcare reform and the impact of drug pricing on the industry.

What are the implications of the statement that '25% is completely misleading'?

How does the speaker feel about the potential for being sued by the company?